Axsome Therapeutics, Inc.
US ˙ NasdaqGM ˙ US05464T1043

SecurityAXSM / Axsome Therapeutics, Inc.
InstitutionPerceptive Advisors Llc
ManagerJoseph Edelman
Latest Disclosed Ownership149,950 shares
Latest Disclosed Value $ 25,344,549
Perceptive Advisors Llc reports 0.71% increase in ownership of AXSM / Axsome Therapeutics, Inc.

On May 29, 2026 - Perceptive Advisors Llc filed a 13F-HR/A form disclosing ownership of 149,950 shares of Axsome Therapeutics, Inc. (US:AXSM) valued at $25,344,549 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 148,900 shares of Axsome Therapeutics, Inc.. This represents a change in shares of 0.71% during the quarter. The current value of the position is $34,836,384 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-29 2026-03-31 13F/A-1 AXSOME THERAPEUTICS COM 05464T104 149,950 1,050 0.71 25,345 -6.81 0.4952
2026-05-15 2026-03-31 13F AXSOME THERAPEUTICS COM 05464T104 149,950 1,050 25,345 0.4959
2026-02-17 2025-12-31 13F AXSOME THERAPEUTICS COM 05464T104 148,900 0 0.00 27,195 50.39 0.4847
2025-11-14 2025-09-30 13F AXSOME THERAPEUTICS COM 05464T104 148,900 -49,634 -25.00 18,084 -12.74 0.5222
2025-08-14 2025-06-30 13F AXSOME THERAPEUTICS COM 05464T104 198,534 -156,573 -44.09 20,725 -49.96 0.7683
2025-08-06 2025-03-31 13F/A-1 AXSOME THERAPEUTICS COM 05464T104 355,107 -308,967 -46.53 41,416 -26.29 1.4631
2025-05-15 2025-03-31 13F AXSOME THERAPEUTICS COM 05464T104 355,107 -308,967 41,416 1.4592
2025-02-14 2024-12-31 13F AXSOME THERAPEUTICS COM 05464T104 664,074 -118,770 -15.17 56,187 -20.14 1.5484
2024-11-14 2024-09-30 13F AXSOME THERAPEUTICS COM 05464T104 782,844 323,733 70.51 70,354 90.36 1.4884
2024-08-16 2024-06-30 13F/A-1 AXSOME THERAPEUTICS COM 05464T104 459,111 -646,230 -58.46 36,958 -58.10 0.8902
2024-08-14 2024-06-30 13F AXSOME THERAPEUTICS COM 05464T104 459,111 -646,230 36,958 0.8801
2024-08-06 2024-03-31 13F/A-1 AXSOME THERAPEUTICS COM 05464T104 1,105,341 67,322 6.49 88,206 6.77 1.5433
2024-05-15 2024-03-31 13F AXSOME THERAPEUTICS COM 05464T104 1,105,341 67,322 88,206 1.5319
2024-02-26 2023-12-31 13F/A-1 AXSOME THERAPEUTICS COM 05464T104 1,038,019 556,370 115.51 82,616 145.43 1.8441
2024-02-14 2023-12-31 13F AXSOME THERAPEUTICS COM 05464T104 1,038,019 556,370 82,616 1.8433
2023-11-14 2023-09-30 13F AXSOME THERAPEUTICS COM 05464T104 481,649 210,156 77.41 33,662 72.55 1.1229
2023-08-24 2023-06-30 13F/A-1 AXSOME THERAPEUTICS COM 05464T104 271,493 271,493 19,509 0.5647
2023-08-14 2023-06-30 13F AXSOME THERAPEUTICS COM 05464T104 271,493 271,493 19,509 0.5656
2022-05-16 2022-03-31 13F AXSOME THERAPEUTICS COM 05464T104 0 -80,420 -100.00 0 -100.00
2022-05-04 2021-12-31 13F/A-2 AXSOME THERAPEUTICS COM 05464T104 80,420 0 0.00 3,038 14.60 0.0468
2022-04-13 2021-12-31 13F/A-1 AXSOME THERAPEUTICS COM 05464T104 80,420 0 3,038 0.0469
2022-02-14 2021-12-31 13F AXSOME THERAPEUTICS COM 05464T104 80,420 0 3,038 0.0469
2021-12-03 2021-09-30 13F/A-1 AXSOME THERAPEUTICS COM 05464T104 80,420 -473,488 -85.48 2,651 -92.91 0.0385
2021-11-15 2021-09-30 13F AXSOME THERAPEUTICS COM 05464T104 80,420 -473,488 2,651 0.0385
2021-08-17 2021-06-30 13F/A-1 AXSOME THERAPEUTICS COM 05464T104 553,908 553,908 37,367 0.4849
2021-08-16 2021-06-30 13F AXSOME THERAPEUTICS COM 05464T104 553,908 553,908 37,367 0.4859
2020-11-16 2020-09-30 13F AXSOME THERAPEUTICS COM 05464T104 0 -50,000 -100.00 0 -100.00
2020-08-17 2020-06-30 13F/A-1 AXSOME THERAPEUTICS COM 05464T104 50,000 50,000 4,114 0.0667
2020-08-14 2020-06-30 13F AXSOME THERAPEUTICS COM 05464T104 50,000 50,000 4,114 66,823.5737
2020-02-19 2019-12-31 13F/A-1 AXSOME THERAPEUTICS COM 05464T104 0 -53,879 -100.00 0 -100.00
2019-11-14 2019-09-30 13F AXSOME THERAPEUTICS COM 05464T104 53,879 0 0.00 1,091 -21.34 0.0294
2019-08-14 2019-06-30 13F AXSOME THERAPEUTICS COM 05464T104 53,879 0 0.00 1,387 80.83 0.0318
2019-05-16 2019-03-31 13F/A-1 AXSOME THERAPEUTICS COM 05464T104 53,879 53,879 767 0.0216
2019-05-15 2019-03-31 13F AXSOME THERAPEUTICS COM 05464T104 53,879 767 0.0216
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.